Intrinsic value of DexCom - DXCM

Previous Close

$138.83

  Intrinsic Value

$66.82

stock screener

  Rating & Target

str. sell

-52%

Previous close

$138.83

 
Intrinsic value

$66.82

 
Up/down potential

-52%

 
Rating

str. sell

We calculate the intrinsic value of DXCM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 11.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  42.10
  38.39
  35.05
  32.05
  29.34
  26.91
  24.72
  22.74
  20.97
  19.37
  17.94
  16.64
  15.48
  14.43
  13.49
  12.64
  11.87
  11.19
  10.57
  10.01
  9.51
  9.06
  8.65
  8.29
  7.96
  7.66
  7.40
  7.16
  6.94
  6.75
Revenue, $m
  1,021
  1,413
  1,908
  2,520
  3,259
  4,136
  5,158
  6,331
  7,659
  9,143
  10,783
  12,577
  14,524
  16,620
  18,861
  21,245
  23,768
  26,427
  29,220
  32,145
  35,203
  38,392
  41,714
  45,171
  48,767
  52,504
  56,388
  60,424
  64,618
  68,978
Variable operating expenses, $m
  867
  1,200
  1,620
  2,139
  2,766
  3,510
  4,377
  5,372
  6,499
  7,757
  9,147
  10,670
  12,321
  14,099
  16,000
  18,023
  20,163
  22,419
  24,788
  27,270
  29,863
  32,568
  35,387
  38,320
  41,370
  44,540
  47,835
  51,258
  54,816
  58,515
Fixed operating expenses, $m
  156
  160
  163
  167
  171
  174
  178
  182
  186
  190
  194
  199
  203
  207
  212
  217
  221
  226
  231
  236
  242
  247
  252
  258
  264
  269
  275
  281
  288
  294
Total operating expenses, $m
  1,023
  1,360
  1,783
  2,306
  2,937
  3,684
  4,555
  5,554
  6,685
  7,947
  9,341
  10,869
  12,524
  14,306
  16,212
  18,240
  20,384
  22,645
  25,019
  27,506
  30,105
  32,815
  35,639
  38,578
  41,634
  44,809
  48,110
  51,539
  55,104
  58,809
Operating income, $m
  -3
  53
  125
  214
  323
  452
  603
  777
  974
  1,195
  1,441
  1,709
  2,000
  2,313
  2,649
  3,006
  3,384
  3,782
  4,201
  4,640
  5,098
  5,576
  6,075
  6,594
  7,134
  7,695
  8,278
  8,884
  9,514
  10,169
EBITDA, $m
  20
  85
  167
  269
  394
  542
  715
  914
  1,140
  1,393
  1,673
  1,980
  2,312
  2,671
  3,055
  3,463
  3,895
  4,351
  4,829
  5,331
  5,855
  6,402
  6,972
  7,566
  8,183
  8,824
  9,491
  10,184
  10,904
  11,653
Interest expense (income), $m
  0
  26
  37
  56
  80
  109
  145
  187
  237
  293
  358
  429
  508
  595
  689
  790
  898
  1,013
  1,135
  1,264
  1,399
  1,540
  1,687
  1,841
  2,002
  2,169
  2,342
  2,523
  2,710
  2,905
  3,108
Earnings before tax, $m
  -28
  16
  69
  134
  213
  307
  416
  540
  681
  838
  1,012
  1,201
  1,405
  1,625
  1,859
  2,107
  2,370
  2,647
  2,937
  3,241
  3,558
  3,889
  4,234
  4,592
  4,965
  5,352
  5,755
  6,174
  6,609
  7,061
Tax expense, $m
  0
  4
  19
  36
  58
  83
  112
  146
  184
  226
  273
  324
  379
  439
  502
  569
  640
  715
  793
  875
  961
  1,050
  1,143
  1,240
  1,341
  1,445
  1,554
  1,667
  1,784
  1,907
Net income, $m
  -28
  12
  50
  98
  156
  224
  303
  394
  497
  612
  739
  877
  1,026
  1,186
  1,357
  1,538
  1,730
  1,932
  2,144
  2,366
  2,598
  2,839
  3,091
  3,352
  3,624
  3,907
  4,201
  4,507
  4,824
  5,155

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  702
  972
  1,312
  1,733
  2,241
  2,845
  3,548
  4,354
  5,268
  6,288
  7,416
  8,650
  9,989
  11,430
  12,972
  14,612
  16,347
  18,175
  20,096
  22,108
  24,211
  26,404
  28,689
  31,067
  33,540
  36,110
  38,781
  41,557
  44,441
  47,440
Adjusted assets (=assets-cash), $m
  702
  972
  1,312
  1,733
  2,241
  2,845
  3,548
  4,354
  5,268
  6,288
  7,416
  8,650
  9,989
  11,430
  12,972
  14,612
  16,347
  18,175
  20,096
  22,108
  24,211
  26,404
  28,689
  31,067
  33,540
  36,110
  38,781
  41,557
  44,441
  47,440
Revenue / Adjusted assets
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
  1.454
Average production assets, $m
  189
  261
  353
  466
  603
  765
  954
  1,171
  1,417
  1,691
  1,995
  2,327
  2,687
  3,075
  3,489
  3,930
  4,397
  4,889
  5,406
  5,947
  6,512
  7,102
  7,717
  8,357
  9,022
  9,713
  10,432
  11,178
  11,954
  12,761
Working capital, $m
  82
  113
  153
  202
  261
  331
  413
  507
  613
  731
  863
  1,006
  1,162
  1,330
  1,509
  1,700
  1,901
  2,114
  2,338
  2,572
  2,816
  3,071
  3,337
  3,614
  3,901
  4,200
  4,511
  4,834
  5,169
  5,518
Total debt, $m
  475
  717
  1,024
  1,403
  1,860
  2,403
  3,036
  3,762
  4,584
  5,502
  6,517
  7,628
  8,833
  10,130
  11,518
  12,993
  14,555
  16,201
  17,930
  19,740
  21,633
  23,607
  25,663
  27,803
  30,029
  32,342
  34,746
  37,244
  39,840
  42,539
Total liabilities, $m
  632
  875
  1,181
  1,560
  2,017
  2,560
  3,193
  3,919
  4,741
  5,659
  6,674
  7,785
  8,990
  10,287
  11,675
  13,150
  14,712
  16,358
  18,087
  19,897
  21,790
  23,764
  25,820
  27,960
  30,186
  32,499
  34,903
  37,401
  39,997
  42,696
Total equity, $m
  70
  97
  131
  173
  224
  284
  355
  435
  527
  629
  742
  865
  999
  1,143
  1,297
  1,461
  1,635
  1,818
  2,010
  2,211
  2,421
  2,640
  2,869
  3,107
  3,354
  3,611
  3,878
  4,156
  4,444
  4,744
Total liabilities and equity, $m
  702
  972
  1,312
  1,733
  2,241
  2,844
  3,548
  4,354
  5,268
  6,288
  7,416
  8,650
  9,989
  11,430
  12,972
  14,611
  16,347
  18,176
  20,097
  22,108
  24,211
  26,404
  28,689
  31,067
  33,540
  36,110
  38,781
  41,557
  44,441
  47,440
Debt-to-equity ratio
  6.760
  7.380
  7.800
  8.090
  8.300
  8.450
  8.560
  8.640
  8.700
  8.750
  8.790
  8.820
  8.840
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.950
  8.960
  8.960
  8.960
  8.960
  8.970
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -28
  12
  50
  98
  156
  224
  303
  394
  497
  612
  739
  877
  1,026
  1,186
  1,357
  1,538
  1,730
  1,932
  2,144
  2,366
  2,598
  2,839
  3,091
  3,352
  3,624
  3,907
  4,201
  4,507
  4,824
  5,155
Depreciation, amort., depletion, $m
  23
  32
  42
  55
  71
  90
  112
  137
  166
  198
  232
  271
  312
  358
  406
  457
  511
  568
  629
  692
  757
  826
  897
  972
  1,049
  1,129
  1,213
  1,300
  1,390
  1,484
Funds from operations, $m
  -5
  43
  93
  153
  227
  314
  416
  532
  663
  810
  971
  1,147
  1,338
  1,543
  1,763
  1,995
  2,242
  2,501
  2,773
  3,057
  3,355
  3,665
  3,988
  4,324
  4,673
  5,037
  5,414
  5,807
  6,215
  6,639
Change in working capital, $m
  24
  31
  40
  49
  59
  70
  82
  94
  106
  119
  131
  144
  156
  168
  179
  191
  202
  213
  223
  234
  245
  255
  266
  277
  288
  299
  311
  323
  336
  349
Cash from operations, $m
  -29
  12
  53
  104
  168
  244
  334
  438
  557
  691
  840
  1,004
  1,182
  1,376
  1,583
  1,805
  2,040
  2,288
  2,549
  2,823
  3,110
  3,410
  3,722
  4,047
  4,386
  4,738
  5,104
  5,484
  5,879
  6,290
Maintenance CAPEX, $m
  -16
  -22
  -30
  -41
  -54
  -70
  -89
  -111
  -136
  -165
  -197
  -232
  -271
  -312
  -358
  -406
  -457
  -511
  -568
  -629
  -692
  -757
  -826
  -897
  -972
  -1,049
  -1,129
  -1,213
  -1,300
  -1,390
New CAPEX, $m
  -56
  -73
  -92
  -113
  -137
  -162
  -189
  -217
  -246
  -275
  -303
  -332
  -360
  -388
  -415
  -441
  -467
  -492
  -517
  -541
  -566
  -590
  -615
  -640
  -665
  -691
  -718
  -747
  -776
  -807
Cash from investing activities, $m
  -72
  -95
  -122
  -154
  -191
  -232
  -278
  -328
  -382
  -440
  -500
  -564
  -631
  -700
  -773
  -847
  -924
  -1,003
  -1,085
  -1,170
  -1,258
  -1,347
  -1,441
  -1,537
  -1,637
  -1,740
  -1,847
  -1,960
  -2,076
  -2,197
Free cash flow, $m
  -100
  -82
  -69
  -50
  -23
  12
  56
  110
  175
  252
  339
  440
  552
  676
  811
  958
  1,116
  1,285
  1,464
  1,654
  1,853
  2,063
  2,282
  2,510
  2,749
  2,997
  3,256
  3,524
  3,803
  4,093
Issuance/(repayment) of debt, $m
  147
  243
  307
  379
  458
  543
  633
  726
  822
  918
  1,015
  1,111
  1,205
  1,297
  1,387
  1,476
  1,562
  1,646
  1,729
  1,811
  1,892
  1,974
  2,056
  2,140
  2,225
  2,313
  2,404
  2,498
  2,596
  2,699
Issuance/(repurchase) of shares, $m
  89
  15
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  236
  258
  307
  379
  458
  543
  633
  726
  822
  918
  1,015
  1,111
  1,205
  1,297
  1,387
  1,476
  1,562
  1,646
  1,729
  1,811
  1,892
  1,974
  2,056
  2,140
  2,225
  2,313
  2,404
  2,498
  2,596
  2,699
Total cash flow (excl. dividends), $m
  135
  175
  238
  329
  434
  554
  688
  836
  997
  1,170
  1,355
  1,550
  1,757
  1,973
  2,199
  2,434
  2,678
  2,931
  3,193
  3,464
  3,746
  4,037
  4,338
  4,650
  4,974
  5,311
  5,660
  6,022
  6,399
  6,792
Retained Cash Flow (-), $m
  -89
  -27
  -34
  -42
  -51
  -60
  -70
  -81
  -91
  -102
  -113
  -123
  -134
  -144
  -154
  -164
  -174
  -183
  -192
  -201
  -210
  -219
  -228
  -238
  -247
  -257
  -267
  -278
  -288
  -300
Prev. year cash balance distribution, $m
  410
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  457
  148
  203
  287
  384
  494
  618
  755
  906
  1,068
  1,242
  1,427
  1,623
  1,829
  2,044
  2,270
  2,504
  2,748
  3,001
  3,263
  3,535
  3,817
  4,110
  4,413
  4,727
  5,053
  5,392
  5,745
  6,111
  6,492
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  438
  136
  177
  236
  297
  359
  418
  472
  520
  560
  590
  609
  617
  614
  600
  577
  545
  506
  462
  415
  366
  317
  269
  225
  184
  147
  116
  89
  67
  49
Current shareholders' claim on cash, %
  52.2
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1
  51.1

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

FINANCIAL RATIOS  of  DexCom (DXCM)

Valuation Ratios
P/E Ratio -178
Price to Sales 20.5
Price to Book 41.4
Price to Tangible Book
Price to Cash Flow 209.7
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate 42.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 69.7%
Cap. Spend. - 3 Yr. Gr. Rate 47.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -19%
Ret/ On Assets - 3 Yr. Avg. -19.2%
Return On Total Capital -26%
Ret/ On T. Cap. - 3 Yr. Avg. -25.4%
Return On Equity -26.1%
Return On Equity - 3 Yr. Avg. -26%
Asset Turnover 1.6
Profitability Ratios
Gross Margin 66%
Gross Margin - 3 Yr. Avg. 67.7%
EBITDA Margin -8.7%
EBITDA Margin - 3 Yr. Avg. -8.6%
Operating Margin -11.2%
Oper. Margin - 3 Yr. Avg. -11.3%
Pre-Tax Margin -11.3%
Pre-Tax Margin - 3 Yr. Avg. -11.4%
Net Profit Margin -11.5%
Net Profit Margin - 3 Yr. Avg. -11.5%
Effective Tax Rate -1.5%
Eff/ Tax Rate - 3 Yr. Avg. -0.5%
Payout Ratio 0%

DXCM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DXCM stock intrinsic value calculation we used $718.5 million for the last fiscal year's total revenue generated by DexCom. The default revenue input number comes from 0001 income statement of DexCom. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DXCM stock valuation model: a) initial revenue growth rate of 42.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DXCM is calculated based on our internal credit rating of DexCom, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of DexCom.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DXCM stock the variable cost ratio is equal to 85%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $153 million in the base year in the intrinsic value calculation for DXCM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 7.8% for DexCom.

Corporate tax rate of 27% is the nominal tax rate for DexCom. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DXCM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DXCM are equal to 18.5%.

Life of production assets of 8.6 years is the average useful life of capital assets used in DexCom operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DXCM is equal to 8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $419.4 million for DexCom - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 84.815 million for DexCom is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of DexCom at the current share price and the inputted number of shares is $11.8 billion.

RELATED COMPANIES Price Int.Val. Rating
TNDM Tandem Diabete 31.35 15.38  str.sell
SENS Senseonics Hol 2.91 0.01  str.sell
JNJ Johnson&Johnso 144.25 176.79  buy
ABT Abbott Laborat 69.41 72.84  hold
DRIO DarioHealth 0.850 0.06  str.sell
WST West Pharmaceu 106.46 54.59  str.sell
CAH Cardinal Healt 57.31 162.77  str.buy

COMPANY NEWS

▶ 3 Growth Stocks Healthcare Investors Should Buy Now   [Nov-09-18 09:01AM  Motley Fool]
▶ IBD Stock Of The Day Flirts With Breakout And Nears Annual Profitability   [Nov-08-18 04:14PM  Investor's Business Daily]
▶ Dexcom to Host Investor Day on December 4, 2018   [Nov-07-18 05:30PM  Business Wire]
▶ DexCom: 3Q Earnings Snapshot   [04:10PM  Associated Press]
▶ 7 Straight-A Stocks to Build a Portfolio Around   [Nov-02-18 02:41PM  InvestorPlace]
▶ Dexcom Announces Release of Clarity Mobile App   [Oct-11-18 04:00AM  PR Newswire]
▶ Investing in Diabetes Stocks: A Beginner's Guide   [Sep-27-18 11:33AM  Motley Fool]
▶ DexCom Inc (NASDAQ:DXCM): Are Analysts Optimistic?   [Sep-18-18 01:01PM  Simply Wall St.]
▶ 10 Boring Stocks Growing Like Weeds   [Sep-14-18 01:05PM  InvestorPlace]
▶ Why DexCom Soared 51.8% in August   [Sep-03-18 11:43AM  Motley Fool]
▶ Dexcom Acquires TypeZero Technologies   [Aug-22-18 04:05PM  Business Wire]
▶ DexCom Stock Skyrockets on Q2 Earnings Beat   [Aug-02-18 02:18PM  InvestorPlace]
▶ Why Dexcom Is Soaring Today   [11:59AM  Motley Fool]
▶ What DexCom Just Said About Its Future   [08:45AM  Motley Fool]
▶ DexCom: 2Q Earnings Snapshot   [05:21PM  Associated Press]
▶ DexCom Announces Upcoming Conference Presentation   [Jul-25-18 08:00AM  Business Wire]
▶ The Three Bullish Charts of DexCom   [Jul-20-18 10:02AM  TheStreet.com]
▶ Top Analysts Say Gamble On These 3 Ace Stocks   [Jul-16-18 09:30AM  TheStreet.com]
▶ 3 Top Growth Stocks to Buy in July   [Jul-11-18 08:30AM  Motley Fool]
▶ Top Stocks Set to Disrupt the Diabetes Market   [Jul-06-18 12:59PM  Motley Fool]
▶ 3 Best Diabetes Stocks of 2018 So Far   [06:34AM  Motley Fool]
▶ Big News Sends Tandem Diabetes Soaring 10.2% Today   [Jun-22-18 12:59PM  Motley Fool]
▶ Dexcom plans 300 hires this year, including 100 this week   [Jun-20-18 04:22PM  American City Business Journals]
▶ DexCom Stock History   [Jun-13-18 07:24PM  Motley Fool]
▶ Dexcom G6® CGM System Receives CE Mark   [Jun-12-18 07:00AM  Business Wire]
▶ Portland-area medical device maker wins another round in federal court   [Jun-04-18 09:22AM  American City Business Journals]
▶ 3 Top Stocks That Aren't on Wall Street's Radar   [May-25-18 03:57PM  Motley Fool]
▶ Five Top MedTech Stocks in Diabetes   [12:40PM  Motley Fool]
▶ DexCom Announces Upcoming Conference Presentation   [May-17-18 08:00AM  Business Wire]
▶ Here's Why DexCom Is Surging Today   [10:49AM  Motley Fool]
▶ DexCom: 1Q Earnings Snapshot   [May-02-18 05:33PM  Associated Press]
▶ Edited Transcript of DXCM presentation 6-Mar-17 9:00pm GMT   [Apr-10-18 04:58PM  Thomson Reuters StreetEvents]
▶ Here's Why Senseonics Holdings Inc. Is Rising Today   [Apr-04-18 03:35PM  Motley Fool]
▶ DexCom reports 4Q loss   [Feb-27-18 05:31PM  Associated Press]
▶ DexCom, Inc. to Host Earnings Call   [12:50PM  ACCESSWIRE]
▶ DexCom Q4 Earnings Preview   [12:29PM  Benzinga]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.